CoChat

Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)

Open access
Chessum, Nicola E. A., Sharp, Swee Y., Caldwell, John J., Pasqua, A. Elisa, Wilding, Birgit, Colombano, Giampiero, Collins, Ian, Ozer, Bugra, Richards, Meirion, Rowlands, Martin, Stubbs, Mark, Burke, Rosemary, McAndrew, P. Craig, Clarke, Paul A., Workman, Paul, Cheeseman, Matthew D., Jones, Keith · 2018 · Journal of Medicinal Chemistry
Cited by 91

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Demonstrating intracellular protein target engagement is an essential step in the development and progression of new chemical probes and potential small molecule therapeutics. However, this can be particularly challenging for poorly studied and noncatalytic proteins, as robust proximal biomarkers are rarely known. To confirm that our recently discovered chemical probe 1 (CCT251236) binds the putative transcription factor regulator pirin in living cells, we developed a heterobifunctional protein degradation probe. Focusing on linker design and physicochemical properties, we generated a highly active probe 16 (CCT367766) in only three iterations, validating our efficient strategy for degradation probe design against nonvalidated protein targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01406

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 50

  1. Swinney, 2004, Biochemical mechanisms of drug action: What does it take for success?, Nat. Rev. Drug Discovery, 3, 801, 10.1038/nrd1500 · DOI · Paper page
  2. Schürmann, 2016, Small-molecule target engagement in cells, Cell Chem. Biol., 23, 435, 10.1016/j.chembiol.2016.03.008 · DOI
  3. Simon, 2013, Determining target engagement in living systems, Nat. Chem. Biol., 9, 200, 10.1038/nchembio.1211 · DOI · Paper page
  4. Durham, 2015, Target engagement in lead generation, Bioorg. Med. Chem. Lett., 25, 998, 10.1016/j.bmcl.2014.12.076 · DOI · Paper page
  5. Sun, 2012, Monitoring protein interactions in living cells with fluorescence lifetime imaging microscopy, Methods Enzymol., 504, 371, 10.1016/B978-0-12-391857-4.00019-7 · DOI
  6. Robers, 2015, Target engagement and drug residence time can be observed in living cells with BRET, Nat. Commun., 6, 10091, 10.1038/ncomms10091 · DOI · Paper page
  7. Franken, 2015, Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry, Nat. Protoc., 10, 1567, 10.1038/nprot.2015.101 · DOI · Paper page
  8. Huber, 2015, Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling, Nat. Methods, 12, 1055, 10.1038/nmeth.3590 · DOI · Paper page
  9. Mateus, 2017, Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes, Proteome Sci., 15, 13, 10.1186/s12953-017-0122-4 · DOI · Paper page
  10. Lanning, 2014, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors, Nat. Chem. Biol., 10, 760, 10.1038/nchembio.1582 · DOI · Paper page
  11. Cheeseman, 2017, Discovery of a chemical probe bisamide (CCT251236): an orally bioavailable efficacious pirin ligand from a heat shock transcription factor 1 (HSF1) phenotypic screen, J. Med. Chem., 60, 180, 10.1021/acs.jmedchem.6b01055 · DOI
  12. Liu, 2013, Pirin is an iron-dependent redox regulator of NF-κB, Proc. Natl. Acad. Sci. U. S. A., 110, 9722, 10.1073/pnas.1221743110 · DOI · Paper page
  13. Dunwell, 2004, Cupins: the most functionally diverse protein superfamily?, Phytochemistry, 65, 7, 10.1016/j.phytochem.2003.08.016 · DOI · Paper page
  14. Komai, 2015, Pirin regulates epithelial to mesenchymal transition independently of BCL3-SLUG signaling, FEBS Lett., 589, 738, 10.1016/j.febslet.2015.01.040 · DOI
  15. Ohoka, 2016, Protein knockdown technology: Application of ubiquitin ligase to cancer therapy, Curr. Cancer Drug Targets, 16, 136, 10.2174/1568009616666151112122502 · DOI · Paper page
  16. Collins, 2017, Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway, Biochem. J., 474, 1127, 10.1042/BCJ20160762 · DOI · Paper page
  17. Toure, 2016, Small-molecule PROTACS: New approaches to protein degradation, Angew. Chem., Int. Ed., 55, 1966, 10.1002/anie.201507978 · DOI · Paper page
  18. Lai, 2017, Induced protein degradation: An emerging drug discovery paradigm, Nat. Rev. Drug Discovery, 16, 101, 10.1038/nrd.2016.211 · DOI · Paper page
  19. Galdeano, 2014, Structure guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities, J. Med. Chem., 57, 8657, 10.1021/jm5011258 · DOI · Paper page
  20. Demizu, 2016, Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand, Bioorg. Med. Chem. Lett., 26, 4865, 10.1016/j.bmcl.2016.09.041 · DOI
  21. Petzold, 2016, Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase, Nature, 532, 127, 10.1038/nature16979 · DOI · Paper page
  22. Crew, 2017, Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1, J. Med. Chem., 10.1021/acs.jmedchem.7b00635 · DOI · Paper page
  23. Zhou, 2017, Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression, J. Med. Chem., 10.1021/acs.jmedchem.6b01816 · DOI · Paper page
  24. Robb, 2017, Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC), Chem. Commun., 53, 7577, 10.1039/C7CC03879H · DOI · Paper page
  25. Ruchelman, 2013, Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity, Bioorg. Med. Chem. Lett., 23, 360, 10.1016/j.bmcl.2012.10.071 · DOI
  26. Lohbeck, 2016, Practical synthesis of a phthalimide-based cereblon ligand to enable PROTAC development, Bioorg. Med. Chem. Lett., 26, 5260, 10.1016/j.bmcl.2016.09.048 · DOI
  27. Georgsson, 2003, Rapid palladium-catalyzed synthesis of esters from aryl halides utilizing Mo(CO)6 as a solid carbon monoxide source, J. Comb. Chem., 5, 350, 10.1021/cc0201086 · doi:10.1021/cc0201086
  28. Georgsson, 2005, Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity, J. Med. Chem., 48, 6620, 10.1021/jm050280z · DOI
  29. Chan, 2017, Impact of target warhead and linkage vector on inducing protein degradation: Comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds, J. Med. Chem., 10.1021/acs.jmedchem.6b01912 · DOI · Paper page
  30. Huang, 2003, Fluorescence polarization competition assay: The range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand, J. Biomol. Screening, 8, 34, 10.1177/1087057102239666 · DOI · Paper page
  31. Munson, 1988, An exact correction to the ″Cheng-Prusoff″ correction, J. Recept. Res., 8, 533, 10.3109/10799898809049010 · DOI · Paper page
  32. Erales, 2014, Ubiquitin-independent proteasomal degradation, Biochim. Biophys. Acta, Mol. Cell Res., 1843, 216, 10.1016/j.bbamcr.2013.05.008 · DOI · Paper page
  33. Mateus, 2017, Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery, Proc. Natl. Acad. Sci. U. S. A., 114, E6231, 10.1073/pnas.1701848114 · DOI · Paper page
  34. Pye, 2017, Nonclassical size dependence of permeation defines bounds for passive adsorption of large drug molecules, J. Med. Chem., 60, 1665, 10.1021/acs.jmedchem.6b01483 · DOI · Paper page
  35. Hann, 2012, Finding the sweet spot: The role of nature and nurture in medicinal chemistry, Nat. Rev. Drug Discovery, 11, 355, 10.1038/nrd3701 · DOI · Paper page
  36. Palm, 1998, Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors, J. Med. Chem., 41, 5382, 10.1021/jm980313t · DOI · Paper page
  37. Gillis, 2015, Applications of fluorine in medicinal chemistry, J. Med. Chem., 58, 8315, 10.1021/acs.jmedchem.5b00258 · DOI · Paper page
  38. George, 2013, Synthesis of iodopyridone, Tetrahedron, 69, 8209, 10.1016/j.tet.2013.07.033 · doi:10.1016/j.tet.2013.07.033
  39. Lepper, 2006, Thalidomide metabolism and hydrolysis: mechanisms and implications, Curr. Drug Metab., 7, 677, 10.2174/138920006778017777 · DOI · Paper page
  40. Reist, 1998, Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites, Chem. Res. Toxicol., 11, 1521, 10.1021/tx9801817 · DOI · Paper page
  41. Goodwin, 2001, Physicochemical determinants of passive membrane permeability: Role of solute hydrogen-bonding potential and volume, J. Med. Chem., 44, 3721, 10.1021/jm010253i · DOI
  42. Evans, 2017, Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex, Chem. Commun., 53, 5167, 10.1039/C7CC01376K · DOI
  43. Youdim, 2003, In vitro trans-monolayer permeability calculations: Often forgotten assumptions, Drug Discovery Today, 8, 997, 10.1016/S1359-6446(03)02873-3 · DOI · Paper page
  44. Filipe, 2014, Beyond Overton’s rule: Quantitative modeling of passive permeation through tight cell monolayers, Mol. Pharmaceutics, 11, 3696, 10.1021/mp500437e · DOI
  45. Owen, 2014, Colloidal drug formulations can explain “bell-shaped” concentration-response curves, ACS Chem. Biol., 9, 777, 10.1021/cb4007584 · DOI
  46. Kisselev, 2001, Proteasome inhibitors: From research tools to drug candidates, Chem. Biol., 8, 739, 10.1016/S1074-5521(01)00056-4 · DOI · Paper page
  47. Diz, 2011, Multiple hypothesis testing in proteomics: A strategy for experimental work, Mol. Cell. Proteomics, 10, M110.004374, 10.1074/mcp.M110.004374 · DOI · Paper page
  48. Thorarensen, 2014, ATP-mediated kinome selectivity: The missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling, ACS Chem. Biol., 9, 1552, 10.1021/cb5002125 · DOI
  49. Smyth, 2009, Measuring and interpreting the selectivity of protein kinase inhibitors, J. Chem. Biol., 2, 131, 10.1007/s12154-009-0023-9 · DOI · Paper page
  50. Knight, 2005, Features of selective kinase inhibitors, Chem. Biol., 12, 621, 10.1016/j.chembiol.2005.04.011 · DOI · Paper page

Cited by

See all 91

Metadata

Authors
Chessum, N. E. A., Sharp, S. Y., Caldwell, J. J., Pasqua, A. E., Wilding, B., Colombano, G., Collins, I., Ozer, B., Richards, M., Rowlands, M., Stubbs, M., Burke, R., McAndrew, P. C., Clarke, P. A., Workman, P., Cheeseman, M. D., & Jones, K.
Venue
Journal of Medicinal Chemistry
Published
2018-01-05
Volume
61
Issue
3
Pages
918-933
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2774715474
Cited by
91
References
20
FWCI
4.66
Type
journal article
Language
en
Open access
hybrid
Funders
Cancer Research UK (C309/A11566, C309/A8274)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b01406
The paper
Chessum, N. E. A., Sharp, S. Y., Caldwell, J. J., Pasqua, A. E., Wilding, B., Colombano, G., Collins, I., Ozer, B., Richards, M., Rowlands, M., Stubbs, M., Burke, R., McAndrew, P. C., Clarke, P. A., Workman, P., Cheeseman, M. D., & Jones, K. (2018). Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b01406

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.